DragonFly EU Pivotal: Transcatheter mitral valve repair for mitral regurgitation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multicenter clinical investigation enrolling adults with symptomatic moderate-to-severe (3+) or severe (4+) degenerative mitral regurgitation (DMR) at high surgical risk and symptomatic functional mitral regurgitation (FMR) who remain symptomatic despite adequate therapy. Participants receive transseptal, femoral-vein implantation of the DragonFly transcatheter mitral valve repair system and are followed at implant, before discharge, 30 days, 6 months, and annually up to 5 years. The DMR cohort uses a group-sequential adaptive design with an interim analysis and possible re-analysis for 160 patients, while the FMR cohort includes adaptive sample size re-estimation with primary endpoint assessment at planned intervals. Local heart teams including an experienced mitral surgeon and cardiologist determine eligibility and manage care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥18 years old
* New York Heart Association (NYHA) Class II-IV
* Moderate to severe (3+) or severe (4+) chronic DMR determined by transthoracic echocardiography (For DMR cohort)
* Symptomatic FMR ≥ 3+ due to ischemic or non-ischemic cardiomyopathy (For FMR cohort)
* Transseptal catheterization and femoral vein access are determined to be feasible
* Subjects have been informed of the nature of the study, understand the purpose of the clinical trial, voluntarily participate in the study, and sign the ICF

Exclusion Criteria:

* Echocardiographic evidence of intracardiac mass, thrombus or vegetation
* Other severe heart valve diseases requiring intervention
* Prior mitral valve leaflet surgery (prior annuloplasty ring not excluded) or previous transcatheter mitral valve intervention
* Acute myocardial infarction occurred within 4 weeks, or untreated severe coronary artery stenosis requiring revascularization
* Any cardiovascular intervention within 30 days or cardiac surgery within 6 months prior to the procedure; or in the judgment of the investigator, the femoral vein cannot accommodate a 25 F catheter or the presence of an inferior vena cava filter would interfere with advancement of the catheter or ipsilateral deep vein thrombosis is present; or the patient's anatomy is not suitable for atrial septal puncture
* Patients in whom TEE or general anesthesia is contraindicated
* End stage heart failure (ACC/AHA stage D); or after heart transplantation; or waiting for a heart transplantation
* Active endocarditis or active rheumatic heart disease; or mitral valve changes due to endocarditis and rheumatic heart valve disease
* History of ischemia cerebrovascular accident in the past 30 days, or severe symptomatic carotid stenosis (ultrasonic examination showed stenosis degree \>70%); or carotid stent implantation within 30 days; hemorrhagic cerebrovascular accident occurred within 6 months
* History of acute peptic ulcer or gastrointestinal bleeding within 3 months
* Hemorrhagic disease or coagulation disorder; or contraindicated of antithrombotic drug treatment
* Modified Rankin scale ≥ 4
* Diseases that make the evaluation of treatment difficult (e.g., cancer, severe metabolic disease, psychosis)
* Pregnant or lactating women
* Hemodynamic instability defined as systolic pressure \< 90 mmHg without afterload reduction medicine, or cardiogenic shock, or need for an intra-aortic balloon pump, or other hemodynamic support devices
* Active infections requiring current antibiotic therapy (if temporary illness, patients may be enrolled 2 weeks after discontinuation of antibiotics)
* Currently participating in an investigational drug or another device study of which the primary endpoint has not been completed, or it that clinically interferes with the current study endpoints. (Note: extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational study)
* In the judgment of the investigator, the patients' compliance will be poor and could not complete the study as required, or other conditions indicate that the subject is not suitable to participate in the study

Where it's running

• Universitatsklinikum Bonn Medizinische Klinik und Poliklinik
  Bonn, Germany Recruiting

Study contacts

• Principal investigator: Francesco Maisano — Ospedale San Raffaele
• Study coordinator: Shuangjie Li
• Email: shuangjie.li@valgenmed.com
• Phone: +8617756106609

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Korea VHD Echo Study: Real-World Practice of Aortic, Mitral, and Tricuspid Valves

  This study looks at how valvular heart disease is managed in Korea by reviewing echocardiograms and medical records from multiple centers to see patterns in disease progression and treatment.

  Recruiting at 2 sites Yonsei University · Seoul, Seoul and 1 other locations · NCT07068633

• Evaluating the MITRIS RESILIA Mitral Valve in Asian Patients

  This study is testing how safe and effective the MITRIS RESILIA mitral valve is for Asian patients who are having surgery to replace their mitral valve.

  Recruiting Asan Medical Center · Seoul, SONGPA-GU · NCT06757049

• Investigating multiple and mixed heart valve diseases

  This study looks at how common different types of heart valve diseases are and their features by gathering information from patients around the world who have been diagnosed with these conditions.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris, Île-de-France Region · NCT06235385

• Evaluating a new device for repairing the mitral valve

  This study is testing a new device to see if it can safely help people with severe mitral valve problems who can't have regular surgery.

  Recruiting at 5 sites Half Moon Medical · New York, New York and 4 other locations · NCT04343313

• Observational registry for patients treated with the NeoChord Artificial Chordae System

  This study is looking at how well the NeoChord Artificial Chordae System works for people with degenerative mitral valve disease over five years, without needing any extra procedures beyond regular treatment.

  Recruiting at 5 sites NeoChord · Bonn and 4 other locations · NCT04190602

• Evaluating imaging parameters in patients with mitral valve insufficiency due to prolapse

  This study is testing how different imaging techniques can help doctors better understand and treat patients with mitral valve problems caused by prolapse.

  Recruiting Lille Catholic University · Lomme, Nord · NCT03962023

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.